BCL2 and acute myeloid leukemia: The BCL2 inhibitor venetoclax was approved by the FDA in 2018 in combination with azacitidine, decitabine, or cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.